| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -15.2 | -20.9 |
| EPS (diluted, $ a share) | $-11.64 | $-56.18 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: MDCX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Medicus Pharma Ltd.: key numbers
- Share price
- $1.69Close, Nov 16
- Market cap
- $3.25M
- Shares outstanding
- 1.92MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Medicus Pharma Ltd.
All →Medicus Pharma Capital Raise of $3M
Medicus Pharma Ltd. entered into a securities purchase agreement for a registered direct offering of 97,973 common shares and 1,646,213 pre-funded warrants for gross proceeds of approximately $3.0 million. Additionally, the company executed a debt-for-equity exchange with Streeterville Capital, LLC, partitioning $10.5 million in principal from an existing secured promissory note into 105,000 non-convertible preferred shares to reduce its debt obligations.
- Value
- $3M
Medicus Pharma Announces $135M M&A Deal
Medicus Pharma announced that its wholly-owned subsidiary, SkinJect, Inc., has entered into a non-binding letter of intent for a business combination with an undisclosed SPAC. The proposed transaction contemplates a $135 million pre-money enterprise valuation for SkinJect and is expected to close in the first half of 2027, with Medicus seeking to retain majority ownership.
- Value
- $135M
“We believe this proposed transaction will represent a meaningful step toward executing our strategic mandate to unlock the value of this important clinical-stage asset for our shareholders. The proposed transaction, in addition to establishing an independent public-market platform and access for Skinject, will also allow Medicus to participate in its future growth”
Dr. Raza Bokhari, Medicus Exec. Chairman and CEO
Medicus Pharma Nasdaq/NYSE Compliance Notice
Medicus Pharma Ltd. regained compliance with Nasdaq's $1.00 minimum bid price requirement after its common shares closed at or above $1.00 for ten consecutive business days. This compliance notice supersedes a delisting determination letter received on October 20, 2026, which had initially triggered a delisting process due to the company's failure to meet the bid price and stockholders' equity requirements.
- Counterparty
- Nasdaq
Medicus Pharma Reverse Stock Split
Medicus Pharma Ltd. implemented a 1-for-50 reverse stock split (share consolidation) of its common shares effective October 12, 2026. The consolidation was previously approved by shareholders at the June 2026 annual meeting and is intended to adjust the company's share count and price on The Nasdaq Capital Market.
Medicus Pharma Reverse Stock Split
Medicus Pharma Ltd. announced a fifty-to-one (1-for-50) reverse stock split of its common shares effective October 12, 2026. The consolidation is intended to increase the per-share bid price to regain compliance with Nasdaq's minimum bid price requirement for continued listing. The split was previously authorized by shareholders at the company's annual meeting on June 3, 2026.
Medicus Pharma Deal Termination with Ya II Pn, Ltd.
Medicus Pharma Ltd. and Yorkville mutually agreed to terminate their $15.0 million Standby Equity Purchase Agreement (SEPA) effective September 11, 2026. At the time of termination, no shares had been issued and no borrowings were outstanding under the facility, with no fees due from either party.
- Counterparty
- YA II PN, LTD.